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PCN33
A COST-CONSEQUENCE ANALYSIS OF DARBEPOETIN ALFA
ADMINISTERED EVERY 3 WEEKS (Q3W_DA) COMPARED TO
WEEKLY EPOETIN ALFA (QW_EA) OR EPOETIN BETA
(QW_EB) IN PATIENTS WITH CHEMOTHERAPY-INDUCED
ANEMIA (CIA):A RETROSPECTIVE STUDY
Van Bellinghen LA1, Demarteau N1,Annemans L1, Bracco A2
1IMS HEOR, Brussels, Belgium, 2Amgen (Europe) GmbH, Zug,
Switzerland
OBJECTIVE: Anemia, a common chemotherapy complication,
is often treated with erythropoiesis-stimulating agents (ESAs),
DA, EA or EB. The objective of this study was to assess, from a
French societal perspective, the cost consequence of Q3W_DA
administration (500 μg) compared to QW_EA or QW_EB at the
European label doses, based on the results of a European retro-
spective observational study. METHOD: A decision-tree model
making explicit the conduct of the patients in the 16-week obser-
vational study (drug administrations, transfusion and response
to treatment) was developed in Excel®. Transition probabilities,
average Hb value over treatment period, number of blood trans-
fusions and ESA administration settings were extracted from the
observational study. Unit costs were applied to medical resources
used (red blood cells packs, health care professional visits, hos-
pital stays) and to patients’ time, further speciﬁed by a panel of
20 French clinical experts. Time was valued at gross hourly wage
rate. Both time and medical costs were extracted from ofﬁcial
sources (AMELI; INSEE) and adjusted to €2006. A 5000-repli-
cations probabilistic sensitivity analysis was performed with
@RISK® using distributions for probabilities (binomial), medical
resources used (triangular), time (triangular) and outcome mea-
sures (normal). RESULTS: Compared to either EA or EB, DA
showed slightly greater increases in Hb levels (0.128 g/dL [95%
CI: −0.160; 0.411] vs. EA; 0.186 g/dL [−1.995; 0.384] vs. EB)
and a lower cost (€−422 [−920; 42.9] vs. EA; −€114 [95% CI:
−452; 211] vs. EB). Probabilistic sensitivity analysis revealed for
DA_Q3W 80% of the replications vs EA and 73% vs EB with
better Hb values and lower costs (dominant); 3% vs EA and
22% vs EB with higher costs and better Hb values. CONCLU-
SION: This analysis provides real-life information to decision
makers about the costs and consequences of Q3W_DA com-
pared to QW_EA and QW_EB. A decision in favor of Q3W_DA
has the highest probability to be beneﬁcial from a health eco-
nomic viewpoint.
PCN34
EFFECT OF METASTASIS LOCALIZATION ON SYMPTOMS
AND ASSISTANCE COSTS IN ADVANCED NSCLC PATIENTS.
FURTHER EVIDENCE FROM THE HABIT STUDY
Negrini C1, Falcone A2
1Pbe consulting, Milano, Italy, 2AstraZeneca, Basiglio, MI, Italy
OBJECTIVES: Study aim was to compare symptom severity and
home assistance burden in advanced non-small-cell-lung cancer
(NSCLC) patients with no metastasis (NM), bony and/or cere-
bral (BCM) metastases and other metastasis localization (OM).
METHODS: A total of 104 advanced NSCLC patients were
enrolled in 18 Italian oncology departments and followed up for
3 months. Main caregiver workload was assessed monthly by a
task scale; activities of other caregivers were also registered and
patients completed the LCS symptoms subscale of the FACT-L
questionnaire. Formal caregiving time was valued according to
market prices; informal caregiving hours were valued using the
wage rate for an equivalent service. RESULTS: Mean age of the
total sample was 65.5 years, males’ prevalence of was over 80%;
principal caregiver was patient’s spouse living with the patient
and non-working in over 70% of cases. Three-monthly mean
total per patient assistance costs amounted to €4431 in BCM, to
€2617 and €2716 in OM and NM patients. Cerebral and/or
bony metastases caused, upon each monthly check, signiﬁcantly
higher assistance costs referred to the main caregiver (p <
0.0001). Higher percentages of patients reported symptoms dete-
rioration in the NM and BCM (45% and 43%) respectively,
while only 23% of patients referred symptom worsening in OM.
CONCLUSION: Home assistance burden was higher in patient
with bony and/or cerebral metastases, other metastasis localiza-
tions showed no impact on caregiving costs and symptom sever-
ity measured by the LCS subscale.
PCN35
BURDEN OF ILLNESS OF RENAL CELL CARCINOMA IN SPAIN
Maroto P1,Villavicencio H2, Piñol C3, Urruticoechea L4
1Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 2Fundació
Puigvert, Barcelona, Spain, 3Q.F. Bayer, S.A., Barcelona, Spain, 4Q.F.
Bayer, S.A., Barcelona, Spain
OBJECTIVE: The incidence of renal cell carcinoma (RCC) in
Spain is about 4000 patients per year. RCC patients have limited
treatment options and low survival rates at 5 years in advanced-
staged patients. Despite the growing importance of RCC, data
on its economic burden are limited. METHODS: An incidence-
based approach was used to estimate the aggregate annual cost
burden from a societal perspective, including costs of medical
treatment and lost productivity due to RCC in Spain. The annual
numbers of patients treated for RCC were classiﬁed by age,
gender and cancer stage (I–IV). The utilization of cancer speciﬁc
treatments, unit costs of these treatments, work-days missed by
these patients and wage rates were included in the model. Data
source included the linked Surveillance, Epidemiology, and End-
results. Data were obtain from publishes literature and experts’
opinion. RESULTS: The annual cost of RCC in Spain (€ 2005)
was found to be €41.8 million (€10,607 per patient). Health-care
costs and lost productivity accounted for 66.3% (€27.8 million)
and 33.7% (€14.1 million) of the total cost, respectively. The
total cost associated with RCC stage II accounted for the highest
portion (43.4%) of the total cost of illness, at €18.2 million. This
reﬂected the highest incidence of RCC at stage II (54% of all
incident cases). Other stages (I, III and IV) accounted for 11.1%
(€4.6 million), 12.1% (€5.1 million) and 33.4% (€14.0 million)
of the overall cost. Per patient cost was remarkably high for stage
IV patients (€17.748), attributable to the high resource utiliza-
tion for this stage. CONCLUSIONS: The economic impact of
RCC in Spain is substantial. New therapies for RCC have the
potential to yield considerable economic and social beneﬁts.
PCN36
BURDEN OF CERVICAL CANCER IN POLAND
Kawalec P1, Glogowski C2, Krzyzanowska A3
1Centrum HTA, Krakow, Poland, 2GSK Commercial Sp. z o.o, Warsaw,
Poland, 3GlaxoSmithKline Poland, Warsaw, Poland
OBJECTIVES: To assess the costs of cervical cancer in Poland
in 2006 measured from the public payer or the societal perspec-
tive. METHODS: The time horizon of the analysis was 12
months and a retrospective approach based on Polish oncology
register was applied. Calculations were performed from the
public payer (direct costs) or societal perspectives (both direct
and indirect costs). Direct medical costs cover diagnostic tests,
surgery, physician consultations and rehabilitation; the unit costs
were obtained from the Polish National Health Fund. Costs from
societal perspective including both costs from public payer point
of view and productivity loss for each clinical state were calcu-
lated on Polish ofﬁcial statistical data; both sick-leave and pre-
mature mortality were taken into account. Number of invasive
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cancer cases was based on the National Cancer Register con-
ducted by the Institute of Oncology in Poland. All calculations
were performed for 2006 (1 Euro = 3.8 PLN. RESULTS: Cost
of yearly treatment of one standard patient was 13.270 PLN
(€3.492) from public payer and 26.429 PLN (€6.955) from soci-
etal perspective respectively. Taking into account cervical cancer
prevalence in Poland (3.439 cases in 2003) and cost per each
case, the total burden of cervical cancer in 2006 was 45.635.530
PLN (€12.009.350) from public payer and 92.290.068 PLN
(€24.286.860) from societal perspective respectively. CONCLU-
SIONS: Cervical cancer is a fatal and costly disease. Indirect
costs are about 50% of total burden of cervical cancer in Poland
in 2006.
PCN37
COMPARING MANAGEMENT PATTERNS AND ASSOCIATED
COSTS FOR WOMEN WITH ABNORMAL CERVICAL
CYTOLOGY IN 5 DIFFERENT COUNTRIES
Rash B1,Van Kriekinge G2
1Health Market International, Ann Arbor, MI, USA, 2GlaxoSmithKline
Biologicals, Rixensart, Brabant, Belgium
OBJECTIVE: To evaluate the management and the management
cost of follow-up of women with abnormal Pap result in 5 coun-
tries (UK, Australia, Germany, Spain & Italy). METHODS: A
retrospective chart review of resource use was conducted in 33
centres within the ﬁve countries. Historical data was collected
on >3000 women with an abnormal Pap smear over a 2-year
treatment and follow-up period starting from year 2002. The
study population was stratiﬁed to include a minimum number of
subjects per cytology category: 35% mild, 25% moderate, 25%
severe dyskaryosis, and 15% cervical cancer. If not enough
cancer cases were enrolled in a country additional cases were
searched for. Unit costs for treatment were calculated from
country-speciﬁc cost databases. We compare overall and
between-countries overall age and age distribution; correlation
between cytology and histology; resource use and cost per his-
tology group after purchasing power parity adjustment.
RESULTS: Overall mean age of patients (n = 3380) was 36.3 y
old (min = 16 y, max = 90 y). Patients with histologically con-
ﬁrmed invasive cancer (n = 333) were on average 48.8 years (min
= 21 y, max = 85 y). Proportion of patients in each conﬁrmed
pre-cancer group was: CIN-1 = 17.1%; CIN-2 = 18.6%; CIN-3
= 29.9%. Negative evaluations after ﬁrst inspection and/or
biopsy were 24% and cancer cases seen and conﬁrmed were
9.9%. The correlation coefﬁcient between cytology and histol-
ogy ﬁndings overall was 62.6, but varied widely across countries.
Resource use such as number of pap smears per stage, colpo-
scopies, and LEEPs shows signiﬁcant differences across countries
and per histology stage (p < 0.05). The initiation of treatment
and type of treatment per histology stage varied considerably
within each country and across the aggregate database. CON-
CLUSION: Weak correlations between cytology and histology
across all countries were observed. Average cost per histology
varies by country and can be substantial. Large cost SDs per his-
tology stage indicate that it remains difﬁcult to standardise treat-
ment for early stages.
PCN38
“COST OF ILLNESS” ANALYSIS OF RENAL CELL CARCINOMA
Lang K1, Danchenko N1, Gondek K2, Schwartz B2,Thompson D1
1i3 Innovus, Medford, MA, USA, 2Bayer Pharmaceuticals Corporation,
West Haven, CT, USA
OBJECTIVES: Renal cell carcinoma (RCC) represents 2–3% of
all malignancies, and is associated with limited treatment options
and low survival rates (median survival for advanced metastatic
disease is estimated at 8–12 months). Despite its importance,
data on the economic burden of RCC are limited. METHODS:
A global, prevalence-based burden-of-illness model was devel-
oped and used to estimate the annual, societal economic burden
of RCC in selected European countries (UK, Spain, France, and
Germany). Key relationships represented in the model include
the annual numbers of patients treated for RCC by age group
and cancer stage; utilization of cancer-speciﬁc treatments; unit
costs of these treatments; work-days missed by these patients,
and wage rates. Local-area data sources were used to populate
the model parameters for each country. Methodological differ-
ences across countries resulting from differences in data avail-
ability are explained. RESULTS: The annual numbers of cases
of RCC include 24,834 in the UK, 3945 in Spain, 35,714 in
France, and 59,864 in Germany. Corresponding estimates of the
aggregate annual burden of RCC (€ 2005) are €541 million,
€41.8 million, €171 million, and €1.6 billion, respectively (per-
patient costs of €21,792, €10,607, €4781, and €26,397). Health
care costs account for between 66% and 89% of the burden in
each country, with lost productivity accounting for the remain-
der. Inpatient care for major surgery, radiofrequency ablation,
arterial embolization, systemic therapy (chemotherapy, radia-
tion, immunotherapy), and associated complications is the
largest driver of health care costs, accounting for approximately
80% or more of the burden in each country. Sensitivity analyses
indicated that results were most sensitive to assumptions regard-
ing health care utilization and unit costs of treatments. 
CONCLUSIONS: The economic burden of RCC in Europe is
substantial. Interventions to reduce the prevalence of RCC have
the potential to yield considerable economic beneﬁts to EU
health systems.
PCN39
COST-UTILITY ANALYSIS IN A FRENCH SETTING OF
ADJUVANT THERAPY WITH HERCEPTIN IN PATIENTS WITH
HER-2 POSITIVE BREAST CANCER
Fagnani F1, Colin X1,Arveux P2, Coudray-Omnès C3
1Cemka-Eval, BOURG-LA-REINE, France, 2CLCC Georges-François
Leclerc, Dijon, France, 3Roche, Neuilly sur Seine, France
OBJECTIVES: Trastuzumab (Herceptin®) combined to
chemotherapy has demonstrated signiﬁcant improvement in time
to progression and survival in metastatic breast cancer patient
overexpressing the receptor of the human growth factor (HER-
2). Herceptin® has recently received a new indication as an 
adjuvant therapy in localised invasive breast cancer and the 
cost-effectiveness of this new add-on therapy needs to be evalu-
ated. METHODS: An analytic Markov Model was established
based on the results of the pivotal clinical study (HERA) and
expert opinion to simulate for an early breast cancer patient 
the course of disease until death. The health states included 
loco-regional and distant recurrences (metastasis), cardiac events
(side-effects), disease free survival and death respectively. This
simulation model projected long-term clinical outcomes and
costs, of adding Herceptin® during one year sequentially to stan-
dard adjuvant therapy versus standard alone (observation).
According to current practices in France, Herceptin® was also
supposed to be used in case of distant recurrences in both arms.
Improvements in lifetime quality adjusted life years (QALY) were
also estimated. Transition probabilities were adjusted on HERA
results. Yearly costs of each health state came from published
sources and from detailed costs observed in one French Oncol-
ogy Centre (G.-F. Leclerc in Dijon). Direct costs and outcomes
were projected over patients’ lifetimes from a French Sickness
Fund perspective. They were both discounted at 3% annually.
Sensitivity analysis was performed. RESULTS: For 1000 patients
